Purpose: Increased bilirubin concentrations may be related to outcome, but this has not been well studied. We evaluated the relationship between total serum bilirubin levels and outcome in critically ill patients. Materials and methods: Data were analyzed from adult critically ill patients included in a 1-day international prevalence study after excluding those with an obvious underlying cause of hyperbilirubinemia. Results: Serum bilirubin concentrations were N1 mg/dL in 2803 (31%) of 8973 patients, and these patients had higher mortality rates than patients with lower bilirubin concentrations (30% vs 21%, P b .01). For serum bilirubin values of 1.1-6 mg/dL, there was a linear increase in crude mortality (R 2 = 0.96), with the highest hospital mortality (42%) in patients with bilirubin concentrations between 3.7 and 6.0 mg/dL. There was no further increase in the mortality rates for patients with bilirubin concentrations N6 mg/dL. A serum bilirubin concentration N1 mg/dL was an independent risk factor for mortality in multilevel analysis.
Introduction
Serum bilirubin concentration is often used as a test of liver function in critically ill patients for 2 important reasons. The first reason is the lack of specific liver function tests. Concentrations of liver enzymes may be increased in all forms of altered tissue perfusion; coagulation tests are altered in many diseases associated with coagulopathy (including disseminated intravascular coagulation) and in patients receiving anticoagulant therapies; and plasma albumin concentration can be decreased in any acute disease. The second reason is pragmatic: bilirubin concentrations are easily measured everywhere and are therefore more easily obtained compared with more sophisticated tests. Accordingly, widely used organ dysfunction scores, such as the Sequential Organ Failure Assessment score (SOFA) [1] , Simplified Acute Physiology Score (SAPS) [2] , and Logistic Organ Dysfunction Score [3] all include bilirubin levels to assess the degree of liver dysfunction.
Increased bilirubin concentrations, as a marker of liver dysfunction, may be expected to be directly related to outcome, but this has not been well studied. High bilirubin concentrations can reflect not only altered hepatic excretory function but also mechanical biliary tract obstruction and hemolysis [4] , problems which can be treated. It is, therefore, not clear whether bilirubin concentrations are directly related to outcome in patients who have no evident cause for their hyperbilirubinemia. The aim of this study was to evaluate the relationship of serum bilirubin concentrations to outcomes in these patients.
Methods
We analyzed the data from adult critically ill patients enrolled in a 1-day (May 7, 2007) Extended Prevalence of Infection in the ICU (EPIC II) study involving 1265 participating intensive care units (ICUs) from 75 countries. Full details of the study methods have been described previously [5] , and a list of participating ICUs is given in the Appendix in the supplemental material. Briefly, this was a prospective study performed to assess the prevalence and types of infection in ICU patients. Demographic, physiological, and therapeutic data were collected from all patients present in a participating ICU on the study day. Patients were followed up until hospital discharge day or for 60 days. Local ethics committees approved the study at each participating center and waived the need for consent because of the purely observational nature.
For the purposes of the present analysis, we excluded patients with a reported admission diagnosis of cirrhosis, acute toxic or alcoholic hepatitis with or without liver failure, cholecystitis with or without cholangitis, acute pancreatitis, or documented hemolysis and those who had had (during the current ICU stay) liver, biliary tract, or pancreatic surgery of any type. Plasma total bilirubin concentrations were considered as normal when ≤1, mildly elevated when between 1.1 and 2 mg/dL, moderately elevated when between 2.1 and 6 mg/dL, and severely elevated when N6 mg/dL, as used in previous studies [6, 7] . Patients who had undergone surgery within the 4 weeks prior to admission were considered as surgical admissions. Sepsis was defined according to standard criteria [8] . SAPS II [2] and SOFA [1] scores were calculated on the study day. Organ failure was defined as a SOFA subscore ≥3 for the organ in question. Multiple organ failure (MOF) was defined as the presence of failure of 2 or more organs, excluding liver failure. Patients were grouped according to the bilirubin concentration on the day of the study (normal, and mild, moderate, and severe hyperbilirubinemia), and each group was stratified into tertiles. Linear and nonlinear regression models were estimated to look at the trend in crude hospital mortality rates.
Statistical analysis
Mild, moderate, and severe forms of hyperbilirubinemia were also investigated as independent risk factors for hospital mortality using a multilevel logistic regression with the structure of a patient admitted to a hospital within a country [9] . Explanatory variables considered in the model included:
-Patient level: type of admission, comorbid conditions, age, sex, mechanical ventilation, shock, sepsis, hemofiltration or hemodialysis, and SAPS II score (calculated without the liver subscore).
-Hospital level: type of ICU (closed vs open, university vs nonuniversity, ICU specialty), number of ICU and hospital beds, number of nurses, presence of 24-h/d in-house intensivist coverage, the presence of emergency and microbiology departments 24 h/d, and the presence of an intermediate care unit.
-Country level: GDP (percentage of gross domestic product spent on health care generated using the WHO Statistical Information System and based on data from 2006).
Bivariate correlations among variables were calculated to check for potential multicollinearity [10] . The results of fixed effects (measures of association) are given as odds ratios (ORs) with their 95% confidence intervals (CIs).
All statistics were 2-tailed, and a P b .05 was considered statistically significant.
Results
Of the 13 796 patients enrolled in the EPIC II study, we excluded 570 patients with an admission diagnosis of cirrhosis, acute alcoholic hepatitis, or toxic hepatitis; 374 patients with an admission diagnosis of acute pancreatitis or pancreatic surgery during their ICU stay; 250 patients with an admission diagnosis of cholecystitis or biliary tract surgery during their ICU stay; and 161 patients with liver surgery during their ICU stay. No patient had documented hemolysis on admission. We also excluded the 3468 patients who had no serum bilirubin concentrations recorded on the day of the study.
Of the 8973 patients included, 2803 had bilirubin concentrations N1 mg/dL (31%): 1516 patients had mild (16%), 698 patients had moderate (8%), and 589 patients had severe (7%) hyperbilirubinemia (Table 1) . On the study day, the majority of the patients had been present in the ICU for more than 72 hours. There were no significant differences in comorbidities between the different groups. Most patients in all groups were admitted for medical diagnoses or emergency surgery ( Table 1) .
The prevalence of hyperbilirubinemia was statistically significantly higher in patients with sepsis than in those without (35% vs 27%, P b .01), in patients receiving mechanical ventilation than in those not mechanically ventilated (40% vs 28% P b .01), and in patients with any type of shock compared with those without shock (43% vs 28%, P b .01). The prevalence of hyperbilirubinemia was similar in surgical and medical patients (32% vs 30%, P = .15).
Patients with hyperbilirubinemia were more likely to have individual organ failures than patients with normal serum bilirubin concentrations, and thus a higher prevalence of MOF (Fig. 1 ). There was a linear increase in hospital mortality for bilirubin concentrations between 1 and 6 mg/dL (R 2 = 0.96), with no further increases in mortality rates for concentrations N6 mg/dL ( Fig. 2 ) In multilevel analysis, hyperbilirubinemia, even mild (OR, 1.38; 95% CI, 1.18-1.62; P b .001), was an independent risk factor for mortality. The highest OR was in patients with moderate hyperbilirubinemia (OR, 1.71; 95% CI, 1.38-2.12; P b .001), and the OR in patients with severe hyperbilirubinemia was 1.54 (95% CI, 1.20-1.97; P b .001) (Fig. 3, eTable 1 ).
Discussion
This large prevalence study of critically ill patients illustrates a specific pattern of mortality rates in relation to different bilirubin concentrations. The relevance of the results is strengthened by the large number of patients and the worldwide nature of the study. The population was purposefully heterogeneous, but we excluded patients with cirrhosis or any other obvious known cause of hyperbilirubinemia. However, almost one third of the patients still had a bilirubin level N1 mg/dL.
The chosen cutoff values we used are somewhat arbitrary but have also been used by other studies [6, 7] . The criteria for hyperbilirubinemia used in the literature vary, with some studies using bilirubin concentrations N2 mg/dL [11] [12] [13] [14] [15] [16] and others N3 mg/dL [17] [18] [19] [20] . The SOFA score gives 0 point for bilirubin levels b1.2 mg/dL, SAPS II score gives 0 for values b4 mg/dL, and the Logistic Organ Dysfunction Score for values b2 mg/dL. We chose to define hyperbilirubinemia as a bilirubin concentration N1 mg/dL because 99% of the general population is expected to have a serum bilirubin less than this value [21, 22] . Indeed, we documented a significant increase in mortality even when bilirubin concentrations were only increased slightly to between 1.1 and 2 mg/dL, supporting the use of 1 mg/dL as the upper normal value. In an earlier monocenter study by Brienza et al [16] , the prevalence of hyperbilirubinemia, defined as values more N2 mg/dL, in critically ill patients was 30%. In our study, only 14% of patients had bilirubin concentrations N2 mg/dL; changes in ventilation strategies and treatment of shock and sepsis over time as well as the different study populations are some possible factors that could explain these differences. The surgical nature of patients did not seem to influence the prevalence of hyperbilirubinemia in our study.
The liver has a dual supply of blood (ie, the hepatic artery and the portal venous system). However, the liver has only limited control over its perfusion because the majority of the liver tissue is perfused from the portal venous system [23] . Liver dysfunction is, therefore, particularly common in patients with altered liver perfusion, such as in shock [24] or sepsis [25] , or even simply during mechanical ventilation [26] . Our data highlight that hyperbilirubinemia is common in these patients and is directly related to outcome.
Multilevel analysis showed that bilirubin is an independent risk factor for increased mortality, supporting the role of altered liver function in multiple organ failure. However, in addition to being a surrogate for hepatic dysfunction in general, bilirubin is not a neutral molecule and may itself affect outcomes. Bilirubin can impair the bactericidal properties of neutrophils through its antioxidative effects [27] and may have nephrotoxic [28] and neurotoxic [29] effects. It can also inhibit inducible nitric oxide synthase [30] and exert platelet antiaggregation effects, possibly by inhibiting collagen-induced platelet activation [31] . However, Vanwijngaerden et al [32] recently suggested that hyperbilirubinemia Chronic heart failure (%) 573 (9) 219 (14) 93 (13) 78 (13) Cancer (%) 687 (11) 148 (10) 96 (14) 66 (11) COPD (%)
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a Statistically significant at P b .05 level compared with normal bilirubin (≤1 mg/dL). b Statistically significant at P b .05 level compared with the other hyperbilirubinemia subgroups. may be an adaptive response to critical illness, and several reports suggest that bilirubin may have beneficial as well as harmful cellular effects [33, 34] .
Our results suggest that the general opinion that the higher the concentration of bilirubin, the higher the mortality in noncirrhotic critically ill patients [11, 35] may need to be revisited because there was a steep and linear increase in mortality rates until the bilirubin reached about 6 mg/dL, but not above this value. The subgroups were numerically equal so that this analysis is solid. Interestingly, the SOFA score gives an additional point for patients with a bilirubin between 6 and 11.9 mg/dL and 2 additional points for higher values. We evaluated only a single value of bilirubin. However, this value likely corresponded to the highest value of bilirubin given that the majority of the patients were assessed after the third day of admission; this time should be sufficient for serum bilirubin to reach its maximum values [36] . The loss of linear correlation between mortality and bilirubin concentrations in patients with severe hyperbilirubinemia is interesting, albeit not easily explained. Although hyperbilirubinemia is relatively common in critically ill patients, very high bilirubin concentrations without any known cause are seen less frequently. For this reason, previous smaller studies have not evaluated this group of patients thoroughly. Importantly, the patients with very high bilirubin concentrations were not more severely ill than those with moderate bilirubin concentrations. It is possible that other mechanisms than just liver dysfunction could account for very high bilirubin concentrations (N6 mg/dL), such as upregulation of multidrug-resistant associated protein 3 [37] or drug-induced cholestasis [38] .
Our results are in accordance with several previous studies that have shown that increased bilirubin is an independent prognostic factor for mortality in patients with sepsis [11, 35] , in trauma patients [13] , or in a heterogeneous population of critically ill patients [15] . In a large multicenter study, Kramer et al [15] evaluated the mortality rates of critically ill noncirrhotic patients in relation to the bilirubin concentrations measured within 48 hours after admission to the ICU. In contrast to our results, they found a linear increase in the ORs for mortality even with high concentrations of bilirubin. However, there may be differences between early and late liver dysfunction [39] , and Kramer et al only evaluated hyperbilirubinemia present in the first 48 hours after admission. Heterogeneity in the populations could be another explanation for these apparent differences. In the study by Kramer et al [15] , there were fewer patients who underwent an emergency operation (34% vs 51%) and fewer patients with sepsis (3% vs 66%) and shock (2% vs 35%) than in our study.
Our study has some limitations. First, because it was a 1-day prevalence study, we may not have evaluated the highest serum bilirubin concentration for some patients, and we were unable to evaluate changes in bilirubin concentrations over time. The confounding effects of variables after the study day were also not considered in the analysis. Nevertheless, a decrease in bilirubin levels following therapeutic interventions may not be related to decreased mortality [40, 41] . Second, the voluntary participation in the study may limit the generalizability of the data. Third, there may have been differences in the quality of bilirubin measurements between the study centers. Finally, although we adjusted for a large number of important risk factors for mortality, the multilevel analysis may not have taken into account other unmeasured factors.
Conclusions
Hyperbilirubinemia with no obvious primary cause is an independent risk factor for mortality in critically ill patients. Any bilirubin concentration N1 mg/dL should be considered as abnormal in critically ill patients, and even small increases in bilirubin concentrations above this value are associated with higher mortality. Increases in bilirubin concentrations N6 mg/dL were not associated with a further increase in mortality. Hospital mortality rates in relation to bilirubin concentration. The groups of patients with bilirubin concentrations ≤1 mg/dL (n = 5970), 1.1-2 mg/dL (n = 1362), 2.1-6 mg/dL (n = 658), and N6 mg/dL (n = 543) were divided into tertiles after excluding those with unknown outcomes. The range of bilirubin concentrations in each tertile is given on the x-axis. Dotted line: trendline (regression analysis) for total population; solid line: trendline (regression analysis) for patients with bilirubin concentrations between 0.9 and 6 mg/dL. Fig. 3 . Mortality ORs (and 95% CI) for mild, moderate, and severe hyperbilirubinemia extracted from the multilevel logistic regression analysis with hospital mortality as the dependent variable.
